Jazz Pharmaceuticals to Present Data Showcasing Vyxeos Clinical Advances at ASH 2021 Annual Meeting
Former TAP Partner
DUBLIN, Nov. 4, 2021 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that 10 new data abstracts from studies exploring Vyxeos development in acute myeloid leukemia (AML) and higher risk myelodysplastic Syndrome (MDS) will be presented at the 63rd American Society of Hematology (ASH) Annual Meeting, which will be held December 11-14, 2021. This includes presentations from investigator-sponsored trials and presentations from collaboration studies with The University of Texas MD Anderson Cancer Center (MD Anderson).
Vyxeos Highlights at ASH include:
- Results for Vyxeos® (daunorubicin and cytarabine) in acute myeloid leukemia (AML) including an oral presentation from a real-world evidence study of Vyxeos use in newly diagnosed patients and a poster presentation from a Phase 1b study of lower-dose Vyxeos in combination with venetoclax in patients with AML who are unfit for intensive chemotherapy.
- Data for Vyxeos use in new patient populations, including oral presentations of two studies of Vyxeos as treatment in higher risk Myelodysplastic Syndrome (MDS).
Vyxeos Presentations
|
Presentation Topic |
Author |
Date / Time (EST) / Session Title / Presentation Number |
|
A Pilot Study of CPX-351 (Vyxeos®) for Transplant Eligible, Higher Risk Patients with Myelodysplastic Syndrome |
Meagan A. Jacoby et al. |
|
|
Real-World Experience of CPX-351 As First-Line Treatment in 188 Patients with Acute Myeloid Leukemia |
Christina Rautenberg et al. |
|
|
CPX 351 As First Line Treatment in Higher Risk MDS. a Phase II Trial By the GFM |
Pierre Peterlin et al. |
|
|
Preliminary Results by Age Group of Treatment with CPX-351 Plus Venetoclax in Adults with Newly Diagnosed AML: Subgroup Analysis of the V-FAST Phase 1b Master Trial |
Vinod Pullarkat et al. |
|
|
Phase 1b Study of Lower-dose CPX-351 Plus Venetoclax As First-line Treatment for Patients with AML Who Are Unfit for Intensive Chemotherapy: Preliminary Safety and Efficacy Results |
Geoffrey L. Uy et al. |
|
|
Real-World Study of the Treatment Patterns of Patients Diagnosed with Therapy-Related AML or AML-MRC in England between 2013 and 2020 Using the Cancer Analysis System Database |
Alex Legg et al. |
|
|
Real-World Study of CPX-351 Treatment Outcomes for Acute Myeloid Leukemia (AML) in England |
Alex Legg et al. |
|
|
Updated Results of a Phase 1/2 Study of Lower Dose CPX-351 for Patients with Int-2 or High Risk IPSS Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia after Failure to Hypomethylating Agents |
Guillermo Montalban-Bravo et al. |
|
|
Liposomal Cytarabine and Daunorubicin (CPX-351) in Combination with Gemtuzumab Ozogamicin (GO) in Relapsed Refractory (R/R) Patients with Acute Myeloid Leukemia (AML) and Post-Hypomethylating Agent (Post-HMA) Failure High-Risk Myelodysplastic Syndrome (HR-MDS) |
Daniel Rivera et al. |
|
|
A Phase II Study of CPX-351 plus Venetoclax in Patients with Relapsed/Refractory (R/R) or Newly Diagnosed Acute Myeloid Leukemia (AML) |
Kunhwa Kim et al. |
|